J & J Brushes Off Looming Biosimilar Competition

Johnson& Johnson sought to reassure investors and analysts that lower-priced competition for one of its top-selling products won ’t slow a company that posted slightly better-than-expected results in the third quarter.

Source: WSJ.com: Health - October 18, 2016 Category: Pharmaceuticals Tags: PAID Source Type: news